Top

Published in:

Open Access 01-06-2018 | Original Paper

Current Perspective on MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder

Authors: Sascha B. Thal, Miriam J. J. Lommen

Published in: Journal of Contemporary Psychotherapy | Issue 2/2018

Abstract

The present paper discusses the current literature with regard to substance-assisted psychotherapy with Methylenedioxymethamphetamine (MDMA) for posttraumatic stress disorder (PTSD). The aim of the paper is to give a comprehensive overview of the development from MDMA’s early application in psychotherapy to its present and future role in the treatment of PTSD. It is further attempted to increase the attention for MDMA’s therapeutic potential by providing a thorough depiction of the scientific evidence regarding its theorized mechanism of action and potential harms of its application in the clinical setting (e.g., misattribution of therapeutic gains to medication instead of psychological changes). Empirical support for the use of MDMA-assisted psychotherapy, including the randomized, double-blind, placebo-controlled trails that have been conducted since 2008, is discussed. Thus far, an overall remission rate of 66.2% and low rates of adverse effects have been found in the six phase two trials conducted in clinical settings with 105 blinded subjects with chronic PTSD. The results seem to support MDMA’s safe and effective use as an adjunct to psychotherapy. Even though preliminary studies may look promising, more studies of its application in a psychotherapeutic context are needed in order to establish MDMA as a potential adjunct to therapy.

Advokat, C. (2007). Literature review: Update on amphetamine neurotoxicity and its relevance to the treatment of ADHD. Journal of Attention Disorders, 11(1), 8–16.PubMedCrossRef

Aldrich, J. (1995). Correlations genuine and spurious in Pearson and Yule. Statistical Science, 10(4), 364–376.CrossRef

American Psychiatry Association. (2013). Diagnostic and statistical manual of mental disorders (5th edn.). Arlington, VA: American Psychiatric Publishing.CrossRef

Amoroso, T. (2015). The psychopharmacology of ± 3,4 methylenedioxymethamphetamine and its role in the treatment of posttraumatic stress disorder. Journal of Psychoactive Drugs, 47(5), 337–344.PubMedCrossRef

Amoroso, T., & Workman, M. (2016). Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: A preliminary meta-analysis and comparison to prolonged exposure therapy. Journal of Psychopharmacology, 30(7), 595–600.PubMedCrossRef

Başoğlu, M., Marks, I. M., Kili, C., Brewin, C. R., & Swinson, R. P. (1994). Alprazolam and exposure for panic disorder with agoraphobia. Attribution of improvement to medication predicts subsequent relapse. The British Journal of Psychiatry, 164(5), 652–659.PubMedCrossRef

Baumgartner, T., Heinrichs, M., Vonlanthen, A., Fischenbacher, U., & Fehr, E. (2008). Oxytocin shapes the neural circuitry of trust and trust adaptation in humans. Neuron, 58, 639–650.PubMedCrossRef

Baylen, C. A., & Rosenberg, H. (2006). A review of acute subjective effects of MDMA/ecstasy. Addiction, 101(7), 933–947.PubMedCrossRef

Bedi, G., Phan, K. L., Angstadt, M., & de Wit, H. (2009). Effects of MDMA on sociability and neural response to social threat and social reward. Psychopharmacology (Berl), 207(1), 73–83.CrossRef

Benedeck, D. M., Friedmann, M. J., Zatzick, D., et al. (2009). Guideline Watch (March 2009): Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. Focus, 7, 204–213.CrossRef

Benzenhöfer, U., & Passie, T. (2006). Zur Frühgeschichte von “Ecstasy”. Der Nervenarzt, 77, 95–99.PubMedCrossRef

Bouso, J. C., Doblin, R., Farré, M., Alcázar, M., & Gómez-Jarabo, G. (2008). MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. Journal of Psychoactive Drugs, 40(3), 225–236.PubMedCrossRef

Bradley, R., Greene, J., Russ, E., Dutra, L., & Westen, D. (2005). A multidimensional meta-analysis of psychotherapy for PTSD. American Journal of Psychiatry, 162(2), 214–227.PubMedCrossRef

Bremner, J. D., Vermetten, E., Schmahl, C., Vaccarino, V., Vythilingam, M., Afzal, N., & Charney, D. S. (2005). Positron emission tomographic imaging of neural correlates of a fear acquisition and extinction paradigm in women with childhood sexual-absue-related post-traumatic stress disorder. Psychological Medicine, 35(6), 791–806.PubMedPubMedCentralCrossRef

Brunt, T. M., Poortman, A., Niesink, R. J. M., & van den Brink, W. (2011). Instability of the ecstasy market and a new kid on the block: Mephedrone. Journal of Psychopharmacology, 25(11), 1543–1547.PubMedCrossRef

Carhart-Harris, R. L., Kevin, M., Robert, L., David, E., Wall, M. B., Bart, F., et al. (2015). The effects of acutely administered 3,4-methylenedioxymethamphetamine on spontaneous brain function in healthy volunteers measured with arterial spin labeling and blood oxygen level-dependent resting-state functional connectivity. Biological Psychiatry, 78(8), 554–562.PubMedPubMedCentralCrossRef

Carhart-Harris, R. L., Wall, M. B., Erritzoe, D., Kaelen, M., Ferguson, B., De Meer, I., & Nutt, D. J. (2014). The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories. International Journal of Neuropsychopharmacology, 17(4), 527–540.PubMedCrossRef

Chabrol, H., & Oehen, P. (2013). MDMA assisted psychotherapy found to have a large effect for chronic post-traumatic stress disorder. Journal of Psychopharmacology, 27, 865–866.PubMedCrossRef

Charuvastra, A., & Cloitre, M. (2008). Social bonds and posttraumatic stress disorder. Annual Review of Psychology, 59, 301–328.PubMedPubMedCentralCrossRef

Cloitre, M. (2009). Effective psychotherapies for posttraumatic stress disorder: A review and critique. CNS Spectrums, 14, 32–43.PubMed

Cole, J. C., & Sumnall, H. R. (2003). Altered states: The clinical effects of ecstasy. Pharmacology & Therapeutics, 98(1), 35–58.CrossRef

Danforth, A., Struble, C., Yazar-Klosinksi, B., & Grob, C. (2016). MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 64, 237–249.CrossRef

De Win, M. M., Jager, G., Vervaeke, H. K., Schilt, T., Reneman, L., Booij, J., & Van Den Brink, W. (2005). The Netherlands XTC Toxicity (NeXT) study: Objectives and methods of a study investigating causality, course, and clinical relevance. International Journal of Methods in Psychiatric Research, 14(4), 167–185.PubMedCrossRef

Degenhardt, L., Bruno, R., & Topp, L. (2010). Is ecstasy a drug of dependence? Drug and Alcohol Dependece, 107(1), 1–10.CrossRef

Doblin, R. (2002). A clinical plan for MDMA (ecstasy) in the treatment of posttraumatic stress disorder (PTSD): Partnering with the FDA. Journal of Psychoactive Drugs, 24(2), 185–194.CrossRef

Doblin, R., Greer, G., Holland, H., Jerome, L., Mithoefer, M. C., & Sessa, B. (2014). A reconsideration and response to Parrot AC (2013) “Human psychobiology of MDMA or ‘ecstasy’: An overview of 25 years of empirical research”. Human Psychopharmacology: Clinical and Experimental, 29, 105–108.CrossRef

Dominique, J.-F., Bentz, D., Michael, T., Bolt, O. C., Wiederhold, B. K., Margraf, J., & Wilhelm, F. H. (2011). Glucocorticoids enhance extinction-based psychotherapy. Proceedings of the National Academy of Sciences, 108(16), 6621–6625.CrossRef

Doukas, A., D’Andrea, W., Doran, J., et al. (2014). Psychophysiological predictors of working alliance among treatment-seeking women with complex trauma exposure. Journal of Traumatic Stress, 27, 672–679.PubMedCrossRef

El Khoury-Malhame, M., Reynaud, E., Soriano, A., Michael, K., Salgado-Pineda, P., Zendjidjian, X., et al. (2011). Amygdala activity correlates with attentional bias in PTSD. Neuropsychologia, 49(7), 1969–1973.PubMedCrossRef

Emerson, A. (2016). Treating PTSD with MDMA-assisted psychotherapy: Product development status and proposed design for phase 3 clinical trials. MAPS Bulletin Annual Reports, 26(3), 26–29.

Emerson, A., Ponté, L., Jerome, L., & Doblin, R. (2014). History and future of the multidisciplinary association for psychedelic studies (MAPS). Journal of Psychoactive Drugs, 46(1), 27–36.PubMedCrossRef

Flatten, G., Gast, U., Hofmann, A., Knaevelsrud, C., Lampe, A., Liebermann, P., et al. (2011). S-3 Leitlinie Posttraumatische Belastungsströrung. Trauma & Gewalt, 3, 202–210.

Foa, E. B., Keane, T. M., Friedman, M. J., et al. (2009). Effective treatment for PTSD, practice guidelines from the international society for traumatic stress studies. New York: Guilford Press.

Foa, E. B., & Kozak, M. J. (1986). Emotional processing of fear: Exposure to corrective information. Psychological Bulletin, 99, 20.PubMedCrossRef

Frijling, J. L., van Zuiden, M., Koch, S. B. J., Nawjin, L., Goslings, J. C., Luitse, J. S., et al. (2014). Efficacy of oxytocin administration early after psychotrauma in preventing the development of PTSD: Study protocol of a randomized controlled trial. BMC Psychiatry, 14, 92. http://www.biomedcentral.com/1471-244X/14/92.

Gamma, A., Buck, A., Berthold, T., Hell, D., & Vollenweider, F. X. (2000). 3,4-Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by (H₂O)-O-15: PET in healthy humans. Neuropharmacology, 23(4), 388–395.

Green, A. R., Mechan, A. O., Elliot, J. M., et al. (2003). The pharmacology and clinical pharmacology of ± 3,4-methylendioxymethamphetamine (MDMA, “ecstasy). Pharmacological Reviews, 55, 463–508.PubMedCrossRef

Greenberg, P. E., Sisitsky, T., Kessler, R. C., Finkelstein, S. N., Brendt, E. R., Davidson, J. R., & Fyer, A. J. (1999). The economic burder of anxiety disorders in the 1990s. Journal of Clinical Psychiatry, 60(7), 427–435.PubMedCrossRef

Greer, G., & Tolbert, R. (1986). Subjective reports of the effects of MDMA in a clinical setting. Journal of Psychoactive Drugs, 18(4), 319–327.PubMedCrossRef

Grinspoon, L., & Bakalar, J. B. (1986). Can drugs be used to enhance the psychotherapeutic process? American Journal of Psychotherapy, 40(3), 393–404.PubMed

Grob, C. S., Poland, R. R., Chang, L., & Ernst, T. (1996). Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: Methodological considerations and preliminary observations. Behavioural Brain Research, 73(1), 103–107.PubMed

Haber, S. N. (2011). Neuroanatomy of reward: A view from the ventral striatum. In J. A. Gottfired (Ed.), Neurobiology of sensation and reward (Chap. 11). Boca Raton, FL: CRC Press. Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK92777. Accessed 5 Jan 2018.

Halpern, J. H., Pope, H. G., Sherwood, A. R., Barry, S., Hudson, J. I., & Yurgelun-Todd, D. (2004). Residual neuropsychological effects of illicit 3,4-methylenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs. Drug and Alcohol Dependence, 75(2), 135–147.PubMedCrossRef

Harris, D. S., Baggott, M., Mendelson, J. H., Mendelson, J. E., & Jones, R. T. (2002). Subjective and hormonal effects of 3,4-menthylendioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl), 25(2), 299–309.

Hoskins, M., Pearce, J., Bethell, A., Dankova, L., Barbui, C., Tol, W. A., et al. (2015). Pharmacotherapy for post-traumatic stress disorder: Systematic review and meta-analysis. British Journal of Psychiatry, 206(2), 93–100.PubMedCrossRef

Hysek, C. M., Domes, G., & Liechti, M. E. (2012). MDMA enhances “mind reading” of positive emotions and impairs “mind reading” of negative emotions. Psychopharamacology, 222(2), 293–302.CrossRef

Jeffreys, M. (2009). Clinician’s guide to medications for PTSD. National Center for PTSD. U. S. Department of Veterana Affairs. Retrieved from http://www.ptsd.va.gov/professional/treatment/overview/clinicians-guide-to-medications-for-ptsd.asp. Accessed 5 Jan 2018.

Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry, 62, 593–602.PubMedCrossRef

Kilpatrick, D. G., Resnick, H. S., Milanak, M. E., Miller, M. W., Keyes, K. M., & Friedman, M. J. (2013). National estimates of exposure to traumatic events and PTSD prevalence using DSM-IV and DSM-5 criteria. Journal of Traumatic Stress, 26(5), 537–547.PubMedPubMedCentralCrossRef

Kirkpatrick, M. G., Baggott, M. J., Mendelson, J. E., Galloway, G. P., Liechti, M. E., Hysek, C. M., & de Wit, H. (2014). MDMA effects consistent across laboratories. Psychopharmacology (Berl), 231(19), 3899–3905.CrossRef

Kirsch, P., Esslinger, C., Chen, Q., Mier, D., Lis, S., Siddhanti, S., et al. (2005). Oxytocin modulates neural circuitry for social cognition and fear in humans. Journal of Neuroscience, 25, 11489–11493.PubMedCrossRef

Krebs, T. S., & Johansen, P. (2012). Methodological weaknesses in non-randomized studies of ecstasy (MDMA) use: A cautionary note to readers and reviewers. Neuropsychopharmacology, 37(4), 1070–1071.PubMedPubMedCentralCrossRef

Le Noury, J., Nardo, J. M., Healy, D., Jureidini, J., Raven, M., Tufanaru, C., & Abi-Jaoude, E. (2015). Restoring study 329: Efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ, 351, 16.

Lieb, R., Schuetz, C., Pfister, H., von Sydow, K., & Wittchen, H. (2002). Mental disorders in ecstasy users: A prospective-longitudinal investigation. Drug and Alcohol Dependence, 68(2), 195–207.PubMedCrossRef

Mathews, A. (2006). Towards an experimental cognitive science of CBT. Behavior Therapy, 37(3), 314–318.PubMedCrossRef

Mithoefer, M. (2013). MDMA-assisted psychotherapy: How different is it from other psychotherapy? Manifesting Minds: A Review of Psychedelics in Science, Medicine, Sex, and Spirituality, 125.

Mithoefer, M., Jerome, L., & Doblin, R. (2003). MDMA (“ecstasy”) and neurotoxicity. Science, 300(5625), 1504–1505.PubMedCrossRef

Mithoefer, M., Wagner, M., Mithoefer, A., Jerome, L., & Doblin, R. (2011). The safety and efficacy of ± 3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: The first randomized controlled pilot study. Journal of Psychopharmacology, 25(4), 439–452.PubMedPubMedCentralCrossRef

Mithoefer, M., Wagner, M., Mithoefer, A., Jerome, L., Martin, S. F., Yazar-Klosinski, B., & Doblin, R. (2013). Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: A prospective long-term follow-up study. Journal of Psychopharmacology, 27(1), 28–39.PubMedPubMedCentralCrossRef

Mithoefer, M. C. (2016). MDMA investigator’s brochure. Retrieved from http://www.maps.org. Accessed 5 Jan 2018.

Morina, N., Wicherts, J. M., Lobbrecht, J., & Priebe, S. (2014). Remission from post-traumatic stress disorder in adults: A systematic review and meta-analysis of long term outcome studies. Clinical Psychology Review, 34(3), 249–255.PubMedCrossRef

Multidisciplinary Association for Psychedelic Studies. (2016). A manual for MDMA-assisted psychotherapy in the treatment of posttraumatic stress disorder. Retrieved from http://www.maps.org. Accessed 5 Jan 2018.

Nichols, D. E., Lloyd, D. H., Hoffman, A. J., Nichols, M. B., & Yim, G. K. (1982). Effects of certain hallucinogenic amphetamine analogues on the release of [3H]serotonin from rat brain synaptosomes. Journal of Medicinal Chemistry, 25(5), 530–535.PubMedCrossRef

Nichols, D. E., & Oberlender, R. (1990). Structure-activity relationships of mdma and related compounds: A new class of psychoactive drugs? Annals of the New York Academy of Sciences, 600, 613–623.PubMedCrossRef

Oehen, P., Traber, R., Widmer, V., & Schnyder, U. (2013). A randomized, controlled pilot study of MDMA (± 3,4-methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD). Journal of Psychopharmacology, 27(1), 40–52.PubMedCrossRef

Olff, M. (2012). Bonding after trauma: On the role of social support and the oxytocin system in traumatic stress. European Journal of Psychotraumatology, 3, 18597. https://doi.org/10.3402/ejpt.v3i0.18597.CrossRef

Parrott, A. C. (2004). MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy: The neuropsychological implications of taking it at dances and raves. Neuropsychobiology, 50, 329–335.PubMedCrossRef

Parrott, A. C. (2006). MDMA in humans: Factors which affect the neuropsychobiological profiles of recreational Ecstasy users, the integrative role of bio-energetic stress. Journal of Psychopharmacology, 20, 147–163.PubMedCrossRef

Parrott, A. C. (2013). Human psychobiology of MDMA or “ecstasy”: An overview of 25 years of empirical research. Human Psychopharmacology: Clinical and Experimental, 28, 289–307.CrossRef

Philipps, D. (2016, November 29). F.D.A. agrees to new trials for ecstasy as relief for PTSD patients. The New York Times. Retrieved from http://www.nytimes.com.

Pilkington, E. (2013). US military struggling to stop suicide epidemic among war veterans. The Guardian. Retrieved from https://www.theguardian.com.

Rauch, S. L., Shin, L. M., & Phelps, E. A. (2006). Neurocircuitry models of posttraumatic stress disorder and extinction: Human neuroimaging research—past, present, and future. Biological Psychiatry, 60, 376–382.PubMedCrossRef

Ricautre, G. A., Yuan, J., Hatzidimitriou, G., Cord, B. J., & McCann, U. D. (2002). Severe dopaminergic neurotoxicity in primates after common recreational dose regimen of MDMA (“ecstasy”). Science, 297(5590), 2260–2263.CrossRef

Schilt, T., de Win, M. M., Jager, G., Koeter, M. W., Ramsey, N. F., Schmand, B., & van den Brink, W. (2008). Specific effects of ecstasy and other illicit drugs on cognition in poly-substance users. Psychological Medicine, 38(9), 1309–1317.PubMedCrossRef

Schuldt, F. M. (2015). MDMA-assisted psychotherapy for posttraumatic stress disorder. Diplomartbeit, Universität Wien. Fakultät für Psychologie.

Sepkowitz, K. (2012). Ecstasy to treat PTSD? Not so fast. Retrieved from https://www.thedailybeast.com/ecstasy-to-treat-ptsd-not-so-fast. Accessed 5 Jan 2018.

Sessa, B. (2011). Could MDMA be useful in the treatment of post-traumatic stress disorder? Progress in Neurology and Psychiatry, 15(6), 4–7.CrossRef

Sessa, B., & Nutt, D. J. (2007). MDMA, politics and medical research: Have we thrown the baby out with the bathwater? Journal of Psychopharmacology, 21(8), 767–791.CrossRef

Shewan, D., Delgarno, P., & Reith, G. (2000). Perceived risk and risk reduction among ecstasy users; the role of drug, set and setting. International Journal of Drug Policy, 10, 431–453.CrossRef

Shulgin, A. T., & Nichols, D. E. (1978). Characterization of three new psychotomimetics: The Pharmacology of Hallucinogens. New York, NY: Pergamon.

Spruit, I. P. (2001). Monitoring synthetic drug markets, trends and public health. Substance Use & Misuse, 36, 23–47.CrossRef

Stein, D. J., Ipser, J., & McAnda, N. (2009). Pharmacotherapy of posttraumatic stress disorder: A review of meta-analyses and treatment guidelines. CNS Spectrums, 14, 25–31.PubMed

Van Etten, M. L., & Taylor, S. (1998). Comparative efficacy of treatments for post-traumatic stress disorder: a meta-analysis. Clinical Psychology and Psychotherapy, 5, 126–144. https://doi.org/10.1002/(SICI)1099-0879(199809)5:3<126::AID-CPP153>3.0.CO;2-H.

Van Minnen, A., Arntz, A., & Keijsers, G. P. J. (2002). Prolonged exposure in patients with chronic PTSD: Predictors of treatment outcome and dropout. Behaviour Research and Therapy, 40, 439–567.PubMedCrossRef

Vollenweider, F. X., Gamma, A., Liechti, M. E., & Huber, T. (1998). Psychological and cardiovascular effects and short-term sequelae of MDMA (“Ecstasy”) in MDMA-naïve healthy volunteers. Neuropsychopharmacology, 19(4), 241–251.PubMedCrossRef

Vollenweider, F. X., Gamma, A., Liechti, M. E., & Huber, T. (1999). Is a single dose of MDMA harmless. Neuropharmacology, 21(4), 598–600.

Vollenweider, F. X., Jones, R. T., & Baggott, M. J. (2001). Caveat emptor: Editors beware. Neuropsychopharmacology, 24(4), 461–463.PubMedCrossRef

Vollenweider, F. X., Liechti, M. E., Gamma, A., Greer, G., & Geyer, M. (2002). Acute psychological and neurophysiological effects of MDMA in humans. Journal of Psychoactive Drugs, 34(2), 171–184.PubMedCrossRef

Vollenweider, F. X., Liechti, M. E., & Paulus, M. P. (2005). MDMA affects both error-rate dependent and independent aspects of decision-making in a two-choice prediction task. Journal of Psychopharmacology, 19(4), 366–374.PubMedCrossRef

Wan, W. (2017). Ecstasy could be “breakthrough” therapy for soldiers, others suffering from PTSD. Retrieved from https://www.washingtonpost.com. Accessed 5 Jan 2018.

Whalen, P. J., Shin, L. M., McInerney, S. C., Fischer, H., Wright, C. I., & Rauch, S. L. (2001). A functional MRI study of human amygdala responses to facial expressions of fear versus anger. Emotion, 1, 70–83.PubMedCrossRef

Wittchen, H. U., Gloster, A., Beesdo, K., Schönfeld, S., & Perkonigg, A. (2009). Posttraumatic stress disorder: Diagnostic and epidemiological perspectives. CNS Spectrums, 14, 5–12.PubMed

Wolff, K., Tsapakis, E. M., Winstock, A. R., Hartley, D., Holt, D., Forsling, M. L., et al. (2006). Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population. Journal of Psychopharmacology, 20, 400–410.PubMedCrossRef

World Health Organization. (2013). Guidelines of the management of conditions that are specifically related to stress. Geneva: WHO.

Zak, P. J., Kurzban, R., & Matzner, W. T. (2005). Oxytocin is associated with human trustworthiness. Hormones and Behavior, 48, 522–527.PubMedCrossRef

Title: Current Perspective on MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder
Authors: Sascha B. Thal
Miriam J. J. Lommen
Publication date: 01-06-2018
Publisher: Springer US
Published in: Journal of Contemporary Psychotherapy / Issue 2/2018
Print ISSN: 0022-0116
Electronic ISSN: 1573-3564
DOI: https://doi.org/10.1007/s10879-017-9379-2

At a glance: The STEP trials

Springer Medicine

Current Perspective on MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2018

Correction to: Current Perspective on MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder

Years of Clinical Experience and Therapist Professional Development: A Literature Review

David F. Tolin: Doing CBT: A Comprehensive Guide to Working with Behaviors, Thoughts, and Emotions

Confronting Patients: Therapists’ Model of a Responsiveness Based Approach

Development of Intensive Motivational Interviewing (IMI) and Modifications for Treating Women with Alcohol Use Disorders

How People Change: Relationships and Neuroplasticity in Psychotherapy, Edited by Marion Solomon and Daniel J. Siegel